Search results for "From ACP Journal Club"
In irritable bowel syndrome, fecal microbiota transplantation improved symptoms at 3 months
While fecal microbiota transplantation was effective in patients with moderate to severe irritable bowel syndrome in a randomized trial, long-term risks of the therapy remain uncertain, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2020/05/22/10.htm
22 May 2020
In reflux-related heartburn unresponsive to PPIs, surgery increased treatment success vs active medical treatment
An ACP Journal Club commentary noted that physicians should not change their practice based on the results of the trial, which are in contrast to the literature and expert opinion, until they are confirmed by studies assessing objective primary end points.
https://gastroenterology.acponline.org/archives/2020/03/27/12.htm
27 Mar 2020
H. pylori eradication therapy may reduce gastric cancer risk; rifabutin-based therapy effective in industry-sponsored trial
A meta-analysis suggested that, in addition to preventing progression, early Helicobacter pylori eradication therapy reduces gastric cancer risk, and a novel rifabutin-based therapy may offer physicians another option for initiating eradication treatment, an ACP Journal Club commentary on both studies said.
https://gastroenterology.acponline.org/archives/2020/09/25/9.htm
25 Sep 2020
H. pylori treatment reduced risk for gastric cancer in patients with a family history of gastric cancer
While results of the trial support a test-and-treat screening approach for Helicobacter pylori in patients with a first-degree relative with gastric cancer, more research is needed before considering universal screening in this population, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2020/06/26/7.htm
26 Jun 2020
After surgery for stage II or III colorectal cancer, more vs less frequent follow-up did not differ for 5-year mortality
The findings help clarify the ideal process for surveillance of clinical recurrence of colorectal cancer, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2018/10/26/7.htm
26 Oct 2018
Pantoprazole did not reduce risk for a composite of upper gastrointestinal events in stable arterial disease
Given the limitations of this large industry-funded trial, the only definitive conclusion one can draw is that patients on aspirin and rivaroxaban with low risk for bleeding may get a very small benefit from long-term proton-pump inhibitor therapy, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2019/10/25/8.htm
25 Oct 2019
In US veterans, PPIs were linked to increased all-cause and some cause-specific mortality compared with H2-blockers
The observational study cannot establish causation, and the only way to prove that proton-pump inhibitors (PPIs) cause the various adverse outcomes attributed to them is to compare them with placebo or no treatment in a randomized trial, according to an ACP Journal Club commentary.
https://gastroenterology.acponline.org/archives/2019/09/27/11.htm
27 Sep 2019
In compensated cirrhosis with portal hypertension, beta-blockers reduced a composite of decompensation or death
The trial results cannot be generalized to all patients with cirrhosis, and future trials should look at whether similar effects could be achieved simply by limiting salt intake, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2019/08/23/10.htm
23 Aug 2019
In uncomplicated acute appendicitis, 61% of patients initially treated with antibiotics had not had appendectomy at 5 years
While delay of surgery was not associated with major complications, potential candidates for nonsurgical management of uncomplicated acute appendicitis should be chosen carefully, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2019/01/25/7.htm
25 Jan 2019
In primary biliary cholangitis, adding bezafibrate to ursodeoxycholic acid increased complete biochemical response
Bezafibrate is currently unavailable in the U.S., but fenofibrate can be offered off-label in these patients with close monitoring of adverse effects, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2018/10/26/8.htm
26 Oct 2018